Log in
Enquire now
‌

US Patent 11208455 Compositions and methods for treating cancer with DuoCARs

Patent 11208455 was granted and assigned to Lentigen on December, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Lentigen
Lentigen
Current Assignee
Lentigen
Lentigen
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11208455
Date of Patent
December 28, 2021
Patent Application Number
16692957
Date Filed
November 22, 2019
Patent Citations Received
‌
US Patent 11802142 Compositions and methods for treating cancer with DuoCARs
‌
US Patent 11878052 Compositions and methods for treating cancer with anti-CD22 immunotherapy
0
Patent Primary Examiner
‌
Maria Marvich
Patent abstract

Novel therapeutic immunotherapy compositions comprising at least two vectors, each vector encoding a functional CAR, whereby the combination of vectors results in the expression of two or more non-identical binding domains, wherein each vector encoded binding domain(s) are covalently linked to a transmembrane domain and one or more non-identical intracellular signaling motifs are provided herein as well as are methods of use of same in a patient-specific immunotherapy that can be used to treat cancers and other diseases and conditions.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11208455 Compositions and methods for treating cancer with DuoCARs

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.